Profile | GDS2987 / GI_29734048-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 25.5 | 61 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | 10.4 | 34 |
GSM215254 | HMVEC_atorvastatin_rep1 | 2.1 | 6 |
GSM215282 | HMVEC_atorvastatin_rep3 | 3.1 | 8 |
GSM215344 | HMVEC_atorvastatin_rep2 | 13 | 32 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 20.2 | 37 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 6.6 | 14 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 31.8 | 46 |
GSM215294 | HMVEC_SLx2119_rep1 | 9.5 | 33 |
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 24.8 | 36 |
GSM215298 | PASMC_vehicle_rep2 | 47.8 | 58 |
GSM215310 | PASMC_vehicle_rep3 | 7.1 | 12 |
GSM215311 | PASMC_atorvastatin_rep1 | 55.2 | 65 |
GSM215312 | PASMC_atorvastatin_rep2 | 38.5 | 52 |
GSM215313 | PASMC_atorvastatin_rep3 | 13.2 | 20 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 12.1 | 21 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 15.5 | 29 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 24 | 39 |
GSM215327 | PASMC_SLx2119_rep1 | 16.7 | 29 |
GSM215328 | PASMC_SLx2119_rep2 | 33.5 | 51 |
GSM215329 | PASMC_SLx2119_rep3 | 9.7 | 19 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 16.9 | 43 |
GSM215332 | Fibroblasts_vehicle_rep3 | 14.9 | 44 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 7 | 19 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 16.4 | 42 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 10.5 | 26 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 31.1 | 63 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 4.2 | 14 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 9.8 | 27 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 19.9 | 50 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 22 | 51 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 44.1 | 66 |